CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We received an updated WNV package insert; please note the manufacturer and license number has been ...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...